Business
Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting
Oncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Rand...
About this update from Oncolytics Biotech Inc.
[{"type":"text","content":"\n\n\n\n\nOncolytics Biotech® Inc. Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nCALGARY, March 2, 2017\n\n\n\n\n\n\n\nNew data evaluating investigational compound REOLYSIN® in combination with paclitaxel in metastatic Breast Cancer \nGrowing understanding of the potential role of REOLYSIN® in treating a broad range of cancers\n\n\nCALGARY, March 2, 2017 /CNW/ - Oncolytics Biotech® Inc. (Oncolytics or the Company) (TSX:ONC) (OTCQX:ONCYF) today announced that the Canadian Cancer Trials Group (CCTG, formerly known as the National Cancer Institute of Canada) will present clinical trial data evaluating the Company's investigational immuno-oncology viral-agent, REOLYSIN®, during the  American Academy of Cancer Research (AACR) Annual Meeting, April 1-5, in Washington, DC. \n\n\"We're very pleased that CCTG has this opportunity to present final data from the metastatic breast cancer study to the international scientific community,\" said Dr. Matt Coffey, President & CEO of Oncolytics.  \n\nThe abstract, authored by Bernstein et al, \"A randomized (RCT) phase II study of oncolytic reovirus (pelareorep) plus standard weekly paclitaxel (P) as therapy for metastatic breast cancer (mBC)\" will be available on the AACR website on March 31, 2017. Submitted by the CCTG, the abstract covers final results from IND 213, an open-label, randomized, non-blinded Phase 2 study to assess the therapeutic combination of intravenously-administered REOLYSIN given in combination with paclitaxel versus paclitaxel alone in patients with advanced or metastatic breast cancer. \n\nOncolytics would like to thank the patients that participated in this study, the CCTG and all the physicians and nurses involved.\n\nAbout Breast CancerThe American Cancer Society estimates there will be 255,180 new cases of breast cancer diagnosed in the United States and 41,070 deaths from the disease in 2017.\n\nAb...